70 related articles for article (PubMed ID: 25443888)
1. Stromal cells attenuate the cytotoxicity of imatinib on Philadelphia chromosome-positive leukemia cells by up-regulating the VE-cadherin/β-catenin signal.
Chen C; Zhang HX; Wang M; Song XG; Cao J; Wang L; Qiao JL; Lu XY; Han ZX; Zhu P; Pan B; Wu QY; Zhao K; Yan ZL; Li ZY; Zeng LY; Xu KL
Leuk Res; 2014 Dec; 38(12):1460-8. PubMed ID: 25443888
[TBL] [Abstract][Full Text] [Related]
2. [Effect of VE-cadherin on sensitivity to Imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
Zhang HX; Yan ZL; Song XG; Lü C; Cao J; Li ZY; Zeng LY; Chen C; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):522-6. PubMed ID: 23827112
[TBL] [Abstract][Full Text] [Related]
3. Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells.
Wang L; O'Leary H; Fortney J; Gibson LF
Blood; 2007 Nov; 110(9):3334-44. PubMed ID: 17638851
[TBL] [Abstract][Full Text] [Related]
4. A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib.
Mancini M; Leo E; Campi V; Castagnetti F; Zazzeroni L; Gugliotta G; Santucci MA; Martinelli G
Cell Signal; 2014 Aug; 26(8):1690-7. PubMed ID: 24747551
[TBL] [Abstract][Full Text] [Related]
5. Imatinib inhibits the expression of SCO2 and FRATAXIN genes that encode mitochondrial proteins in human Bcr-Abl⁺ leukemia cells.
Papadopoulou LC; Kyriazou AV; Bonovolias ID; Tsiftsoglou AS
Blood Cells Mol Dis; 2014; 53(1-2):84-90. PubMed ID: 24726617
[TBL] [Abstract][Full Text] [Related]
6. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
[TBL] [Abstract][Full Text] [Related]
7. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
[TBL] [Abstract][Full Text] [Related]
8. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
[TBL] [Abstract][Full Text] [Related]
9. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
10. The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell.
Shi R; Lin J; Gong Y; Yan T; Shi F; Yang X; Liu X; Naren D
Anticancer Drugs; 2015 Oct; 26(9):913-22. PubMed ID: 26186064
[TBL] [Abstract][Full Text] [Related]
11. Enhanced adhesion/migration and induction of Pyk2 expression in K562 cells following imatinib exposure.
Ovcharenko A; Granot G; Rokah OH; Park J; Shpilberg O; Raanani P
Leuk Res; 2013 Dec; 37(12):1729-36. PubMed ID: 24176282
[TBL] [Abstract][Full Text] [Related]
12. [Effects of stromal cells on sentitivity to imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
Zhang H; Chen C; Yan Z; Song X; Chen W; Li D; Qiu T; Zhang P; Zeng L; Li Z; Xu K
Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):460-4. PubMed ID: 26134008
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Schultz JD; Sommer JU; Hoedt S; Erben P; Hofheinz RD; Faber A; Thorn C; Hörmann K; Sauter A
Oncol Rep; 2012 Jan; 27(1):270-80. PubMed ID: 21993766
[TBL] [Abstract][Full Text] [Related]
15. Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias.
Nemoto A; Inukai T; Uno K; Kiyokawa N; Miyagawa Y; Takahashi K; Sato H; Akahane K; Hirose K; Honna-Oshiro H; Goi K; Kagami K; Nakazawa S; Fujimoto J; Inaba T; Sugita K
Leuk Res; 2013 Jan; 37(1):93-101. PubMed ID: 23099235
[TBL] [Abstract][Full Text] [Related]
16. RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells.
Wang H; Yu J; Zhang L; Xiong Y; Chen S; Xing H; Tian Z; Tang K; Wei H; Rao Q; Wang M; Wang J
Biochem Biophys Res Commun; 2014 Apr; 446(4):1204-10. PubMed ID: 24680683
[TBL] [Abstract][Full Text] [Related]
17. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
[TBL] [Abstract][Full Text] [Related]
18. Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment.
Tsai HJ; Kobayashi S; Izawa K; Ishida T; Watanabe T; Umezawa K; Lin SF; Tojo A
Cancer Sci; 2011 Nov; 102(11):2014-21. PubMed ID: 21777350
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor.
Nagao R; Ashihara E; Kimura S; Strovel JW; Yao H; Takeuchi M; Tanaka R; Hayashi Y; Hirai H; Padia J; Strand K; Maekawa T
Cancer Lett; 2011 Dec; 312(1):91-100. PubMed ID: 21906872
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
